Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review

Journal of Nephrology

Volumn 27, Issue 5, 2014, Pages 483-494

  Russo, Roberto ^a   Ruospo, Marinella ^b   Cozzolino, Mario ^c   De Nicola, Luca ^d   Icardi, Andrea ^e   Paoletti, Ernesto ^f   Mazzaferro, Sandro ^g  

^a POLICLINICO   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e ASL 3   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Parathyroid hormone; Peritoneal dialysis; Pleiotropic effects; Proteinuria; Vitamin D; Vitamin D analogs

Indexed keywords

22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; ALFACALCIDOL; ALKALINE PHOSPHATASE; BRAIN NATRIURETIC PEPTIDE; PARATHYROID HORMONE; PARICALCITOL; SECALCIFEROL; VITAMIN D DERIVATIVE; BIOLOGICAL MARKER; CALCIFEDIOL; PTH PROTEIN, HUMAN; VITAMIN D;

DATA EXTRACTION; HEMODIAFILTRATION; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; MEMBRANE PERMEABILITY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PLEIOTROPY; PROTEIN DEPLETION; PROTEINURIA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VITAMIN D DEFICIENCY; ADVERSE EFFECTS; BLOOD; DIET SUPPLEMENTATION; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CALCIFEDIOL; DIETARY SUPPLEMENTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84920467388     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0120-x     Document Type: Review

References (98)

1. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289:F8–F28
2. Bikle D, Siiteri P, Ryzen E, Haddad J (1985) Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 61:969–975
3. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281
4. KDIGO Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int 76:s1–s130
5. Jain AK, Blake P, Cordy P, Garg AX (2012) Global trend in rates of peritoneal dialysis. J Am Soc Nephrol 23:533–544
6. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thandhani RI, Chiu YW et al (2009) Chronic kidney disease, hypovitaminosis D and mortality in the United States. Kidney Int 76:931–933
7. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF et al (2008) Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 87:1631–1638
8. Cho HY, Hyun HS, Kang HG, Ha IS, Cheong HI (2013) Prevalence of 25(OH) vitamin D insufficiency and deficiency in pediatric patients on chronic dialysis. Perit Dial Int 33:398–404
9. Clayton P, Singer R (2009) 25-Hydroxyvitamin D levels in prevalent Australian dialysis patients. Nephrology 14:554–559
10. Gracia-Iguacel C, Gallar P, Qureshi AR, Ortega O, Mon C, Ortiz M et al (2010) Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 20:359–367
11. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B (1996) Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 49:506–511
12. Aloni Y, Shany S, Chaimovitz C (1983) Losses of 25-hydroxyvitamin in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. Miner Electrolyte Metab 9:82–86
13. Sahin G, Kirli I, Sirgamul B, Colak E, Yalcin AU (2009) Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients. Int Urol Nephrol 41:989–996
14. Prytula A, Wells D, McLean T, Balona F, Gullet A, Knott C et al (2012) Urinary and dialysate losses of vitamin D-binding protein in children on chronic peritoneal dialysis. Pediatr Nephrol 27:643–649
15. Rosen CJ (2011) Clinical practice. Vitamin D insufficiency. New Engl J Med 364:248–254
16. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M (2013) Renal anemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 28:1672–1679
17. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P et al (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88–95
18. Li YC (2010) Renoprotective effects of vitamin D. Kidney Int 78:134–139
19. Doorenbos CR, van der Born J, Navis G, de Borst MH (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 5:691–700
20. Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M et al (2012) VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <150 pg/mL: results of the Italian FARO survey. Nephrol Dial Transplant 27:3588–3594
21. Taskapan H, Ersoy FF, Passadakis PS, Tam P, Memmos DE, Katopodis KP et al (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 66:247–255
22. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E et al (2011) Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 26:1024–1032
23. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A et al (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508–1515
24. Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437–444
25. Bidmon HJ, Gutkowska J, Murakami R, Stumpf WE (1991) Vitamin D receptors in heart: effects on atrial natriuretic factor. Experentia 47:958–962
26. Chen S, Wu J, Hsieh JC, Whitfield GK, Jurutka PW, Haussler MR et al (1998) Suppression of ANP gene transcription by liganded vitamin D receptor. Involvement of specific receptor domains. Hypertension 31:1338–1342
27. Weishaar RE, Simpson RU (1987) Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 253:E657–E683
28. Weishaar RE, Kim SN, Saunders DE, Simpson RU (1990) Involvement of vitamin D3 with cardiovascular function. III Effects on physical and morphological properties. Am J Physiol 258:E134–E142
29. Obineche EN, Saadi H, Benedict S, Pathan JY, Frampton CM, Nicholls MG (2008) Interrelationships between B-type natriuretic peptides and vitamin D in patients on maintenance peritoneal dialysis. Perit Dial Int 28:617–621
30. Schaubel DE, Blake PG, Fenton SA (2001) Trends in CAPD technique failure: Canada, 1981–1997. Perit Dial Int 21:365–371
31. Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V et al (2013) Treatment with oral active vitamin d is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS ONE 8:e67836
32. 3 on peritoneal immune-cell cytokine release and fibroblast proliferation in CAPD patients. Adv Perit Dial 5:111–120
33. 3 in human macrophages from CAPD patients. Kidney Int 59:69–75
34. 3. Kidney Int 37:1310–1315
35. Liu PT, Stenger S, Li H, Tan BH, Krutzik SR, Ochoa MT et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773
36. Rudnicki M, Kerschbaum J, Hausdorfer J, Mayer G, Konig P (2010) Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin D. Perit Dial Int 30:541–548
37. Lorenzo V, Aracho R, Zamora J, Rufino M, Torres A (2010) Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 25:835–841
38. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869
39. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF et al (2005) Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 20:396–403
40. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK (2008) Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 51:724–731
41. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823–2828
42. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z et al (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249–255
43. Fishbane S, Chittinemi H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54:647–652
44. De Nicola L, Conte G, Russo D, Gorini A, Minutolo R (2012) Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin–angiotensin system: a prospective observational study. BMC Nephrol 13:150
45. Gonzales E, Rojas-Rivera J, Polanco N, Morales E, Morales JM, Egido J et al (2013) Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation 95:e49–e52
46. Coronel F, Rodriguez-Cubillo B, Cigarran S, Gomis A (2011) Effects of paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients. Adv Perit Dial 27:130–133
47. Coronel F, Cigarran S, Gomis A, Rodriguez-Cubillo B, Herrero JA, Delgado P et al (2012) Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol—a preliminary study. Clin Nephrol 78:93–99
48. Sánchez-Álvarez JE, Rodríguez-Suárez C, Coronel-Aguilar D, Gonzàlez-Diaz I, Nùnez-Moral M, Pelàez-Requejo B et al (2013) Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. Nefrologia 33:70–76
49. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Peritoneal Biopsy Study Group et al (2002) Morphological changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479
50. Braun N, Fritz P, Biegger D, Kimmel M, Reimold F, Ulmer C et al (2011) Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum—implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int 31:291–300
51. Hirose M, Nishino T, Obata Y, Nakazawa M, Nakazawa Y, Furusu A et al (2013) 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model. Perit Dial Int 33(2):132–142
52. Li Y, Spataro BC, Yang J, Dai C, Liu Y (2005) 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 68:1500–1510
53. Mazzaferro S, Goldsmith D, Larsson TE, Massy ZA, Cozzolino M (2014) Vitamin D metabolites and/or analogs: which D for which patient? Curr Vasc Pharmacol 12:339–349
54. Bagnis C, Dullo F, Gabella P, Vitale C, D’Elia P, Marangella M et al (1998) Biochemical and hormonal short term effects of 25 hydroxy vitamin D in patients on CAPD. Ital J Min Elect Metab 12:73–76
55. Buccianti G, Bianchi ML, Valenti G, Lorenz M, Cresseri D (1990) Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis. Nephron 56(4):353–356
56. 3 suppresses the serum parathyroid hormone levels of dialysis patients. Nephron 58:283–287
57. Shah N, Bernardini J, Piraino B (2005) Prevalence and correction of 25(OH)D deficiency in peritoneal dialysis patients. Perit Dial Int 25:362–366
58. Bouchard J, Ouimet D, Vallée M, Leblanc M, Pichette V (2008) Effect of vitamin D supplementation on calcidiol and parathyroid hormone levels. Perit Dial Int 28(5):565
59. Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG et al (1987) “High-dose” calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89–95
60. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV et al (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166
61. Felipe C, Miranda B, Selgas R, Martinez ME, Miquel JL, Moreno F et al (1990) Secondary hyper-parathyroidism in CAPD patients: its suppressibility with high doses of calcitriol. Adv Perit Dial 6:238–241
62. Quesada JM, Rodriguez M, CalderondelaBarca JM, Alvarez-Lara A, Martin-Malo A, Mateo A et al (1995) Effect of calcitriol replacement on serum calcitonin and parathyroid hormone levels in CAPD patients. Nephrol Dial Transplant 10:70–74
63. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M (1992) Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 19:540–545
64. Kawabe M, Schreiber MJ, Cosentino FA (1993) Intermittent minibolus oral vitamin D3 in CAPD patients with resistant parathyroid hormone values. Adv Perit Dial 9:264–270
65. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B et al (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211
66. Newman L, Ferrara KA, Tessman MJ, Hart J, Cacho CP (1997) Oral pulsed calcitriol protocol reduces the prevalence of hyperparathyroidism in a PD unit. Adv Perit Dial 13:244–248
67. Scanziani R, Dozio B, Bonforte G, Surian M (1994) Effects of calcitriol pulse therapy per os in CAPD patients. Adv Perit Dial 10:270–274
68. Romanini D, Gazo A, Bellazzi R, de Vincenzi A, Nai M, Santagostino M (1994) Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD. Adv Perit Dial 10:267–269
69. Juergensen P, Santacroce S, Mooraki A, Cooper K, Finkelstein FO, Kliger AS (1994) Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients. Adv Perit Dial 10:259–260
70. Juergensen PH, Finkelstein FO, Cooper K, Santacroce S, Kliger AS (1993) Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol. Adv Perit Dial 9:257–259
71. Bajo MA, Selgas R, Possante C, Aquilera A, Sanchez C, Diaz C et al (1997) Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients. Adv Perit Dial 13:239–243
72. Bechtel U, Mücke C, Feucht HE, Schiffl H, Sitter T, Held E (1995) Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 25:291–296
73. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M (1998) Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 13:1234–1241
74. Vieth R, Ledermann SE, Kooh SW, Balfe JW (1989) Losses of calcitriol to peritoneal dialysis bags and tubing. Perit Dial Int 9:277–280
75. Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC et al (1990) Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 16:126–132
76. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907–914
77. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N et al (1987) The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31(3):795–799
78. Chan H, Tsang WK, Chan CM, Fung SK, So SO, Tang HL et al (1998) Intraperitoneal pulse calcitriol in the treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 18:177–182
79. Arora N, Sandroni S, Moles K (1992) Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol. Adv Perit Dial 8:62–64
80. Malberti F, Scanziani R, Corradi B, Dozio B, Bonforte G, Imbasciati E et al (1994) High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 9:1813–1815
81. 3 therapy in children treated with peritoneal dialysis. Clin Nephrol 42:44–49
82. Gadallah M, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K (2000) Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 16:303–307
83. Cano F, Azocar M, Guerrero JL, Delucchi MA, Lillo AM, Emilfork M et al (2007) Intraperitoneal calcitriol in infants on peritoneal dialysis. Perit Dial Int 27:681–686
84. Rolla D, Paoletti E, Marsano L, Mulas D, Peloso G, Cannella G (1993) Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentration in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int 13(2):118–121
85. Wadhwa NK, Suh H, Howell N, Cabralda T, Sokunbi D, Solomon M (1993) Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients. Adv Perit Dial 9:260–263
86. Chagnac A, Ori Y, Weinstein T, Zevin D, Korzets A, Hirsh J et al (1997) Hypercalcemia during pulse vitamin D3 therapy in CAPD patients treated with low calcium dialysate: the role of decreasing serum parathyroid hormone. J Am Soc Nephrol 8(10):1579–1586
87. −1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. J Intern Med 244:121–131
88. Chagnac A, Ori Y, Weinstein T, Herman M, Korzets A, Zevin D et al (1999) Calcium balance during pulse alfacalcidol therapy for secondary hyperparathyroidism in CAPD patients treated with 1.0 and 1.25 mmol/L dialysate calcium. Am J Kidney Dis 33:82–86
89. Saarinen TT, Arikoski P, Holmberg C, Ronnholm K (2007) Intermittent or daily administration of 1-alpha calcidol for nephrectomized infants on peritoneal dialysis? Pediatr Nephrol 22:1931–1938
90. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R et al (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79:112–119
91. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ et al (2005) Sevelamer controls parathyroid hormone induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16:2501–2508
92. Kubota M, Iwanaga Y, Ishiguro N (2003) The effect of intraperitoneal 22-oxacalcitriol on secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients (IPOX study). Adv Perit Dial 19:227–230
93. Hamada C, Hayashi K, Shou I, Inaba M, Ro Y, Io H et al (2005) Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit Dial Int 25:570–575
94. Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M et al (2003) Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 63(2020):63
95. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS et al (2008) Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28:97–106
96. Jamaluddin EJ, Gafor AHA, Yean LC, Cader R, Mohd R, Kong NC et al (2014) Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 18:507–514
97. Ramos R, Fontan MP, Sanchez E, Bajo A, Barbosa F, Borràs M et al (2013) Effectiveness of treatment with oral paricalcitol in patients on peritoneal dialysis: a Spanish multicenter study. Clin Nephrol 79:394–401
98. Melamed ML, Eustace JA, Plantiga L, Jaar BG, Fink NE, Parekh RS et al (2006) Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351–357